NASDAQ: SPRYArs Pharmaceuticals Inc Stock Ownership - Who owns Ars Pharmaceuticals?
Insider buying vs selling
Have Ars Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Eric Karas | Chief Commercial Officer | 2026-06-12 | 25,000 | $10.00 | $250.00kSell |
| Alexander A. Fitzpatrick | Chief Legal Officer | 2026-06-12 | 3,355 | $10.00 | $33.55kSell |
| Eric Karas | Chief Commercial Officer | 2026-06-12 | 25,000 | $1.50 | $37.50kBuy |
| Brian Dorsey | Chief Operating Officer | 2025-11-13 | 21,828 | $8.71 | $190.06kSell |
| Brian Dorsey | Chief Operating Officer | 2025-11-13 | 21,828 | $0.64 | $13.97kBuy |
| Justin Chakma | Chief Business Officer | 2025-11-12 | 30,000 | $0.84 | $25.20kBuy |
| Justin Chakma | Chief Business Officer | 2025-11-12 | 136,380 | $8.86 | $1.21MSell |
| Justin Chakma | Chief Business Officer | 2025-11-12 | 30,000 | $8.91 | $267.36kSell |
SPRY insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when SPRY insiders and whales buy or sell their stock.
SPRY Shareholders
What type of owners hold Ars Pharmaceuticals Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Richard E. Lowenthal | 22.07% | 21,952,529 | $90.22M | Insider |
| Sarina Tanimoto | 20.47% | 20,360,336 | $83.68M | Insider |
| Orbimed Advisors LLC | 17.12% | 17,029,398 | $69.99M | Insider |
| Peter A. Thompson | 17.12% | 17,029,398 | $69.99M | Insider |
| James E. Flynn | 9.83% | 9,774,508 | $40.17M | Insider |
| Pratik Shah | 4.50% | 4,474,554 | $18.39M | Insider |
| Jonathan D. Root | 4.47% | 4,445,960 | $18.27M | Insider |
| Rajeev Dadoo | 3.03% | 3,009,677 | $12.37M | Insider |
| Presidio Management Group XII LLC | 2.23% | 2,221,798 | $9.13M | Insider |
| Thilo Schroeder | 1.92% | 1,910,029 | $7.85M | Insider |
SPRY vs Biotech Stocks
Ars Pharmaceuticals Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.